Current Treatment Options for DLBCL Besides R-CHOP Chemotherapy

Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

Jason Westin, MD, MS, FACP, director, Lymphoma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, and associate professor at The University of Texas MD Anderson Cancer Center, discusses the current treatment options for patients with diffuse large B-cell lymphoma (DLBCL) that are available besides rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP).

For patients with DLBCL, the other frontline option is a modified chemotherapy regimen, such as dose-adjusted R-EPOCH. In addition, the combination of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) or cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate (CODOX-M) are also modified versions of R-CHOP that are available for patients with DLBCL.